1 Azithromycin Treatment Response as a Probe to Attribute Bacterial Aetiologies of

2 Diarrhoea using Molecular Diagnostics: A Reanalysis of the AntiBiotics for

3 Children with severe Diarrhoea (ABCD) Trial

4

- 5 Jennifer Cornick¹, Sarah Elwood², James Platts-Mills², Patricia Pavlinac^{3,4}, Karim
- 6 Manji⁵, Chris Sudfeld⁶, Christopher P. Duggan^{6, 7}, Queen Dube¹, Naor Bar-Zeev⁸, Karen
- 7 Kotloff^{9,10}, Samba O Sow¹¹, Sunil Sazawal¹², Benson O Singa^{13,14}, Judd L Walson^{13,15},
- 8 Farah Qamar¹⁶, Tahmeed Ahmed¹⁷, Ayesha De Costa¹⁸, Elizabeth T Rogawski
- 9 McQuade¹⁹

10

11 Affiliations:

12 1. Department of Pediatrics, Queen Elizabeth Central Hospital, Blantyre, Malawi. 2. Division of Infectious Diseases and International Health, Department of Medicine, 13 14 University of Virginia, Charlottesville, VA, USA. 15 3. Department of Global Health, University of Washington, Seattle, WA, USA 4. Department of Epidemiology, University of Washington, Seattle, WA, USA. 16 17 5. Department of Pediatrics and Child Health, Muhimbili University of Health and Allied 18 Sciences, Dar es Salaam, Tanzania. 6. Department of Global Health and Population, Harvard T.H. Chan School of Public Health, 19 20 Boston, MA, USA. 7. Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, 21 22 Boston, MA, USA 23 8. International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, 24 Baltimore, MD, USA. 25 9. Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore. 26 27 10. Department of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. 28 29 11. Centre pour le Développement des Vaccins, Bamako, Mali. 30 12. Center for Public Health Kinetics, New Delhi, Delhi, India.

- 31 13. Childhood Acute Illness and Nutrition Network, Nairobi, Kenya.
- 32 14. Kenya Medical Research Institute, Nairobi, Kenya
- 15. Departments of International Heath, Medicine and Pediatrics, Johns Hopkins University,
 Baltimore, MD, USA
- 35 16. Department of Pediatrics and Child Heath, Aga Khan University, Karachi, Pakistan.
- 36 17. Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease
 37 Research, Dhaka, Bangladesh
- 38 18. Department of Maternal, Child, and Adolescent Health and Aging, World Health
 39 Organization, Geneva, Switzerland
- 40 19. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta,
 41 GA, USA
- 42

43 Abstract

44 Background

- 45 Multi-pathogen molecular diagnostics enable assignment of diarrhoea aetiology, but
- 46 defining thresholds of pathogen quantity to accurately attribute aetiology is challenging
- 47 in high-burden settings where coinfections are common. The Antibiotics for Children
- 48 with severe Diarrhoea (ABCD) trial provides an opportunity to leverage the azithromycin
- 49 treatment response to inform which diarrhoea episodes are bacterial.
- 50

51 Methods

52 We analysed data from ABCD, which randomized children with watery diarrhoea to

azithromycin or placebo. We quantified heterogeneity in the azithromycin treatment

- response by the quantity of enteric pathogens detected by qPCR as a tool for
- 55 understanding aetiology.

56

57 Results

58 The heterogeneity in azithromycin treatment response was most prominent for *Shigella*.

59 The risk ratio for diarrhoea on day 3 post enrolment for azithromycin compared to

- 60 placebo was 13% (95% CI:3, 23) lower per log10 increase in Shigella quantity. The
- 61 protective effect of azithromycin on diarrhoea at day 3 also became stronger as
- 62 pathogen quantities increased for Vibrio cholerae, ST-ETEC, and tEPEC. No
- association between pathogen quantity and azithromycin response was observed for

Campylobacter, LT-ETEC or EAEC. The associations were consistent for the outcome
of 90-day hospitalisation or death.

66

67 Conclusions

- 68 The relationships between response to azithromycin treatment and bacterial pathogen
- 69 quantities observed for Shigella, Vibrio cholerae, ST-ETEC and tEPEC confirm prior
- vidence that these pathogens are the likely cause of diarrhoea when detected at high
- 71 quantities. The lack of a similar response pattern for *Campylobacter*, LT-ETEC or EAEC
- is consistent with the limited association between pathogen quantity and diarrhoea
- 73 symptoms previously observed in large studies of diarrhoea aetiology.

75 **Key message** (3 succinct bullet points, each a single sentence)

76	1.	We investigated whether heterogeneity in treatment response observed in the	
77		ABCD trial, where children with diarrhoea were randomised to receive	
78		azithromycin or placebo, could be used to inform aetiological attribution of	
79		diarrhoea to bacterial enteric pathogens.	
80			
81	2.	The protective effect of azithromycin on diarrhoea at day 3 and hospitalisation or	
82		death at day 90 became stronger as pathogen quantities increased for Shigella,	
83		Vibrio cholerae, ST-ETEC and tEPEC but not for Campylobacter, LT-ETEC or	
84		EAEC.	
85			
86	3.	The relationships between Shigella, Vibrio cholerae, ST-ETEC and tEPEC	
87		quantity and response to antibiotic treatment confirm prior evidence that these	
88		pathogens are the likely cause of diarrhoea when detected at high quantities and	
89		could be used to inform which diarrhoea cases should be treated with antibiotics.	
90			

91 Introduction

92 Diarrhoeal diseases are the second leading cause of death in children under five, with 93 the highest burden of disease experienced in low- and middle- income countries 94 (LMICs) (1). Accurate estimates of the burden of specific aetiologies of diarrhoea are 95 necessary for global resource allocation and policy making and may be useful to inform 96 appropriate treatment measures beyond the WHO IMCI recommended management (2). Quantitative PCR (qPCR) diagnostics have been used to attribute likely diarrhoea 97 98 aetiologies in multiple large global studies, including the Global Enteric Multicentre 99 Study (GEMS) (3), the Malnutrition and the Consequences for Child Health and 100 Development (MAL-ED) study (4), and the Global Paediatric Diarrhoea Surveillance 101 network (5).

102

103 The Antibiotics for Children with severe Diarrhoea (ABCD) study, a 7-country, 104 randomized, double-blinded, placebo-controlled trial assessed if a 3-day course of 105 azithromycin reduced mortality or improved linear growth among children with acute 106 watery diarrhoea accompanied by dehydration or undernutrition (6). Rotavirus (21.1%) 107 was the leading cause of diarrhoea, while 28.3% of diarrhoeal cases had a likely 108 bacterial aetiology, most commonly Shigella, ST-ETEC, and typical EPEC (7). While the 109 impact of azithromycin among all enrolled children was minimal, molecular diagnostics 110 revealed that azithromycin was effective at reducing risk of day 3 diarrhoea and day 90 111 hospitalization or death among children with likely bacterial diarrhoea (7). Due to the 112 absence of diarrhoea-free controls in ABCD, pathogen-specific quantity cut-offs were 113 applied to assign etiology, based on the strong associations of those quantities with

diarrhoea previously observed in MAL-ED and GEMS (3,4). However, there was a
residual benefit of azithromycin among episodes with bacteria detected at a lower
quantity. For example, children with a likely bacterial aetiology had a 3.1% absolute
reduction in risk of 90-day hospitalization or death when treated with azithromycin
compared to a 2.3% reduction among children with bacteria detected but not attributed
(7). These findings suggest the previously used cut-offs likely missed true bacterial
episodes that also responded to treatment.

121

122 The ABCD study provides a unique opportunity to further explore diarrhoeal aetiology 123 based on azithromycin treatment response. Azithromycin is a broad-spectrum antibiotic 124 with known efficacy against Gram-negative pathogens, including ETEC (8) 125 *Campylobacter* spp (9) and *Shigella* spp (10,11). We therefore expect an azithromycin 126 treatment response in many cases of diarrhoea in which bacteria are the true 127 aetiological agent. We investigated if heterogeneity in the treatment response by 128 pathogen quantity can further refine aetiological quantity cut-offs for enteric bacteria 129 leading to more precise aetiologic assignment of diarrhoeal episodes. 130

131 Methods

The ABCD study design (12), primary analysis results (6), and post-hoc analyses
incorporating qPCR enteric pathogen testing (13) have been previously described.
Briefly, children 2-23 months of age were enrolled between June 2017 and July 2019
from seven sites in Bangladesh, India, Kenya, Malawi, Mali, Pakistan, and Tanzania if
they presented to study hospitals with acute watery diarrhoea. To be included, children

had to have some or severe dehydration and/or moderate wasting or severe stunting,
as previously defined (12) and could not have received antibiotics in the 2 weeks prior
to presentation. Children with clear indications for antibiotic treatment (i.e., dysentery,
severe acute malnutrition, signs of other infections requiring antibiotics) were excluded.

141

142 Enrolled children were randomized to receive either three days of azithromycin (10 143 mg/kg/day) or placebo. Before randomisation, study staff collected whole stool or a 144 flocked rectal swab which was tested for enteric pathogens by qPCR for the first 145 approximately 1,000 children enrolled at each site, using the TagMan array card 146 platform as described previously (12). To account for differences in sample type, cycle 147 thresholds (Ct's) derived from rectal swabs were adjusted by the pathogen-specific 148 mean cycle threshold difference between paired rectal swabs and whole stools. Follow-149 up visits were conducted to ascertain presence of diarrhoea on day 3 after enrolment 150 and rehospitalisation and vital status 90 days after enrolment.

151

Pathogens were analysed using the continuous Ct as a marker of relative pathogen quantity. To define co-aetiologies (i.e., coinfections at a quantity associated with diarrhoea), we used the pathogen-specific qPCR Ct cut-offs derived for ABCD (7) from two large multisite studies of diarrhoea that included non-diarrhoeal controls, GEMS (3) and MAL-ED (4). A co-aetiology was defined as the detection of any other pathogen at a quantity above (or equally, a qPCR Ct below) the aetiological cut-off. To maximize power to detect treatment effect heterogeneity and to be consistent with prior analyses

(7), the primary outcome assessed in this analysis was presence of diarrhoea 3 days
after enrolment. As a secondary outcome, we considered a combined outcome of
rehospitalisation or death by 90 days after enrolment.

162

For each pathogen previously associated with diarrhoea (3) or with at least 5% 163 164 prevalence, we modelled the heterogeneity in the azithromycin treatment effect by pathogen quantity detected using log-binomial regression adjusting for the day of 165 diarrhoea on which the sample was collected and co-detection of other pathogens. Co-166 167 detection of other pathogens was specified with two variables representing the sum of 168 the episode-specific attributable fractions for all bacteria and the sum of the episode-169 specific attributable fractions for all viruses and protozoa. Episode-specific attributable 170 fractions (AFes) were derived using attribution models from GEMS and MAL-ED by 171 applying pathogen quantities from ABCD diarrhoea episodes and taking the median of 172 1000 estimates drawn equally from each of the site-specific models (5). We first 173 included an interaction term between treatment arm assignment and the quantity of 174 pathogen detected when specified with a linear and quadratic term. We conducted a 175 linear trend test for each interaction using the Wald-based p-value for the quadratic 176 interaction term with alpha = 0.05. Because the test was not statistically significant for 13 of 15 pathogens evaluated (Table S1), we proceeded with modelling the interactions 177 178 with only linear terms for pathogen quantity across all pathogens for interpretability and 179 comparability. For the diarrhoea on day 3 outcome, we further stratified the models by 180 presence of a bacterial co-aetiology.

181

182 We report the model-predicted pathogen quantity and treatment arm-specific risk of 183 each outcome conditional on sample collection at day 0 and no co-detections using 184 gppredict from the ggeffects package v. 1.2.1 in R v. 4.2.1. We report the risk ratio for 185 azithromycin compared to placebo for each outcome by pathogen quantity using the 186 interplot 0.2.3 package, both overall and stratified by presence of a bacterial co-187 aetiology for the diarrhoea on day 3 outcome. These data were summarized by 188 reporting the change in the effect of azithromycin per each log10 increase in pathogen 189 guantity based on the interaction term between pathogen guantity and azithromycin. To 190 estimate the proportion of episodes that could be attributed to each bacterial pathogen 191 based on the azithromycin treatment response, we calculated population attributable 192 fractions from these episode-specific risk ratios for day 3 diarrhea. Specifically, to 193 remove azithromycin effects unrelated to the pathogen detected, we divided each 194 episode-specific risk ratio by the largest risk ratio when pathogen quantity was zero 195 (RR_{adi}). The population attributable fraction was then calculated as $\sum_{i=1}^{n} 1 - RRadj_i$ (since 196 azithromycin is protective) where *i* included all episodes in which the pathogen was 197 detected at any quantity. Adjusted risk ratios were constrained to be less than or equal 198 to 1 such that the episode attributable fraction could not be negative.

199

Finally, across the range of cycle threshold values, we calculated the proportion of diarrhoea episodes that would be treated with antibiotics if a given pathogen-specific cycle threshold were chosen as the cut-off to define aetiology and assign treatment. This proportion was calculated among diarrhoea episodes overall to quantify the proportion of all diarrhoea episodes that would be treated using a given cut-off and

among diarrhoea episodes with the pathogen detected at any quantity to quantify the

206 proportion of all potentially pathogen-attributable episodes that would be treated.

207

208 Results

We included 6692 children who were among the first 1000 enrolled at each of the seven ABCD trial sites and had their samples tested by qPCR with valid a result. This represents 80.9% of all children enrolled in the ABCD trial (n=8268). The density of quantities detected for each pathogen was similar between azithromycin and placebo groups (Figure S1).

214

215 The overall risk of diarrhoea on day 3 was 10.2% and was higher in the placebo 216 (12.0%) compared to azithromycin (8.4%) group. For a subset of the enteric bacteria, 217 specifically Shigella, ST-ETEC, tEPEC, and Vibrio cholerae, azithromycin was more 218 strongly protective for diarrhoea on day 3 as pathogen quantity detected increased. For 219 these pathogens, the risk of diarrhoea on day 3 in the placebo group increased with 220 increasing pathogen quantity, while the risk in the azithromycin group was less 221 dependent on pathogen quantity (Figure 1A). Correspondingly, the effect of 222 azithromycin became stronger (i.e., risk ratios further from the null) as pathogen 223 quantities increased (Figure 1B). The heterogeneity in azithromycin effect by pathogen 224 quantity was most striking and statistically significant only for Shigella. The risk ratio for 225 diarrhoea on day 3 for azithromycin compared to placebo was 13% (95% CI: 3, 23) 226 lower (i.e., further from the null) per log10 increase in Shigella quantity detected (Table

227 1). This translated to detection at a high quantity (Ct = 25) associated with a 50% 228 reduction (95% CI: 30, 64) in diarrhoea on day 3 compared to a 40% reduction (95% CI: 229 33, 75) associated with detection at Ct = 30. A similar pattern was observed for V. 230 cholerae, ST-ETEC, and tEPEC, though the effect heterogeneity was not statistically 231 significant for these pathogens. When stratifying by whether there was a bacterial co-232 aetiology, the association between pathogen quantity and azithromycin treatment 233 response was slightly stronger for episodes in which there was no co-aetiology (Figure 234 1C).

235

236 In contrast, there was no association between pathogen quantity detected and 237 azithromycin treatment response for Campylobacter jejuni/coli, LT-ETEC, and EAEC. 238 For *C. jejuni/coli*, the risk of diarrhoea on day 3 was higher with increasing pathogen 239 quantities detected in both the azithromycin and placebo groups (Figure 1A). This 240 resulted in risk ratios for diarrhoea on day 3 closer to the null at high C. jejuni/coli 241 guantities. For LT-ETEC, the risk of diarrhoea on day 3 was very similar between 242 azithromycin and placebo groups at high quantities detected, and for EAEC, the risk 243 ratio for diarrhoea on day 3 was independent of pathogen quantity.

244

For viruses and parasites, the azithromycin treatment response was inversely associated or was not associated with pathogen quantity detected (Figure 2). For example, for rotavirus, norovirus GII, adenovirus 40/41, and astrovirus, the risk ratio of diarrhoea on day 3 was closer to the null with higher pathogen quantities detected.

There was no consistent pattern when stratifying by presence of a bacterial coaetiology. *Cryptosporidium* was an outlier; higher quantities detected were associated with a larger azithromycin treatment response. This was not explained by the presence of a bacterial co-aetiology. Rather, the azithromycin treatment response was more strongly associated with *Cryptosporidium* quantity for episodes without a bacterial coaetiology.

255

256 These results were consistent for the combined outcome of rehospitalisation or death by 257 day 90, but the associations were less precise and none of the effect heterogeneity was 258 statistically significant (Figure 3 and Figure 4). The risk of death or hospitalisation was 259 4.5% overall, 3.6% in the azithromycin group and 5.3% in the placebo group. For 260 episodes in which Shigella was detected at a higher quantity (Ct=25), azithromycin was 261 associated with a 57% reduction (95% CI: 29%, 70%) in rehospitalisation or death, 262 compared to a 44% reduction (95% CI: 37%, 54%) for episodes with Shigella detected 263 at a lower Ct=30 quantity. The only discrepant result was for rotavirus, for which higher 264 guantities were associated with slightly stronger azithromycin treatment response.

265

Using the azithromycin treatment response as a probe to attribute aetiology, we estimated that 4.14% of episodes could be attributed to *Shigella*, 2.95% could be attributed to ST-ETEC, 2.94% could be attributed to tEPEC, and 0.37% could be attributed to *Vibrio cholerae*. The population attributable fractions for *Campylobacter jejuni/coli*, EAEC, and LT-ETEC were zero.

271

272	The proportion of aetiology-specific and overall diarrhoea episodes that would be
273	treated if treatment decisions were based on pathogen quantity cut-offs depended on
274	the distribution of pathogen quantities among aetiology-specific episodes and the
275	distribution of etiologies (Figure 5). For example, treatment of all episodes with tEPEC
276	detected at a Ct of 25 or lower would result in 50% of episodes with tEPEC treated and
277	8% of episodes treated overall. In contrast, treatment of all episodes with V. cholerae
278	detected at a Ct of 25 or less would result in only 16.6% of episodes with V. cholerae
279	treated and 0.4% of episodes treated overall.

280

281 Discussion

282 In this reanalysis of the qPCR data from the ABCD study, the azithromycin treatment 283 response at day 3 was stronger among episodes with higher detected pathogen 284 guantities for some of the most common bacterial causes of diarrhoea: Shigella, V. 285 cholerae, tEPEC, and ST-ETEC. This supports that these bacteria are likely the true 286 aetiology of diarrhoea when detected at high pathogen quantities. While not statistically 287 significant for all pathogens, the observed heterogeneity in effects by pathogen quantity 288 was largely consistent with previous comparisons of qPCR data between diarrhoea 289 cases and non-diarrhoeal controls from GEMS, which showed strong quantity 290 dependent associations between all these bacterial pathogens and diarrhoea, with the 291 exception of tEPEC; the highest quantities of tEPEC were only moderately associated 292 with diarrhoea in GEMS (3). However, tEPEC was strongly associated with mortality in 293 GEMS, providing additional support for tEPEC as an important cause of diarrhoea (15).

294

295 Our data suggest that the relationship between treatment response and bacterial 296 pathogen quantity is approximately linear, making the assignment of a definitive cycle 297 threshold cut-off for diarrhoeal aetiology difficult. Such a cut-off would be needed to 298 define antibiotic treatment decision rules (i.e., treat if quantity < threshold and not if 299 quantity > threshold) as well as to define case definitions for studies with pathogen-300 specific outcomes (e.g., Shigella-attributed diarrhea for a Shigella vaccine trial). 301 Pathogen quantity could however be used to guide treatment decisions, for example by 302 choosing to treat at a quantity threshold corresponding to a clinically meaningful 303 treatment benefit if a derivative of this assay becomes available as a point of care test. 304 The choice of threshold should also consider the potential benefits of expanded use of 305 azithromycin to treat episodes of bacterial diarrhoea in the context of the growing 306 azithromycin resistance rates in key Gram-negative bacteria, including Shigella spp 307 (16, 17).

308

309 The lack of associations between pathogen quantity and azithromycin treatment 310 response for Campylobacter, LT-ETEC, and EAEC were consistent with the weaker 311 associations between pathogen quantities and diarrhoea observed for these pathogens 312 in MAL-ED and GEMS (3,4). These prior studies of diarrhoea aetiology attributed 313 relatively few diarrhoea episodes to these pathogens compared to their prevalence 314 during diarrhoea, and our results corroborate that they may be relatively rare causes of 315 diarrhoea in children in low-resource settings who have early and high levels of 316 exposure. Sub-clinical carriage of these pathogens is frequent, complicating the

assignment of a cut-off to attribute diarrhoea to this pathogen (18). Low qPCR cut-offs
used to attribute *Campylobacter* diarrhoea based on MAL-ED and GEMS, for example
used in the previous analysis of the ABCD study, have been criticized as potentially
being poorly sensitive (7). However, the lack of treatment response even among
episodes with high *Campylobacter* quantity support the use of a low Ct (i.e., high
quantity) cut-off for attributing *Campylobacter a*etiology.

323

324 A key purpose of vaccine probe studies is to identify the proportion of disease 325 attributable to the vaccine-targeted pathogen (19). In this "antibiotic probe" study 326 analogue, we estimated population attributable fractions for the bacterial pathogens 327 based on the azithromycin treatment response at observed pathogen quantities. The 328 resulting relative ranking of pathogens matched that previously reported in GEMS and 329 MAL-ED (20,21). However, the proportions attributable were smaller in magnitude, likely 330 because azithromycin is not perfectly effective in preventing diarrhoea on day 3. 331 Importantly, no fraction of diarrhoea could be attributed to Campylobacter, EAEC, or LT-332 ETEC using the azithromycin treatment response as a probe given the inverse 333 associations between quantities of these pathogens and the treatment response.

334

We also predominantly observed an inverse association between non-bacterial (virus and parasite) quantities and treatment response at day 3. High viral quantities were strongly associated with poor treatment outcomes, suggesting the true aetiology of these diarrhoeal cases was viral, as we would not expect an azithromycin treatment

response in cases of viral diarrhoea. The observation of improved treatment outcomes
at lower virus quantities, may be due to the increased likelihood of bacterial co-infection
at lower virus quantities, such that the virus was carried at sub-clinical levels while the
aetiology was truly bacterial.

343

344 Interestingly, higher quantities of rotavirus were associated with a small reduction in rates of death or hospitalisation at day 90. Dehydration and/or undernourishment were 345 inclusion criteria for the ABCD study. Malnourishment can suppress the immune 346 347 system; the WHO recommends routine treatment of children with severe acute 348 malnutrition (SAM) with a broad-spectrum antibiotic and in some settings azithromycin 349 administration for SAM has been reported to improve recovery and reduce mortality 350 rates (18). Studies conducted in both Africa and Asia have reported that rotavirus 351 infection is associated with under nutrition (22,23). It is possible that the improved 352 azithromycin treatment outcome observed for higher quantities of rotavirus in this study. 353 is due to the anti-inflammatory effects of azithromycin to treat malnutrition, which may have led to improved recovery from rotavirus infection (24). Further, improved outcomes 354 355 could also be a result of azithromycin driven gut microbiota ablation, which has previously been shown to enhance humoral immunity and reduce severity of rotavirus 356 357 diarrhoea (25).

358

For parasites, high *Giardia* quantities were strongly associated with poor treatment
outcomes. Interestingly, *Cryptosporidium* was unique amongst the non-bacterial

pathogens such that high quantities were associated with improved treatment response at both day 3 and day 90. This improvement was not explained by presence of bacterial co-infections but has been observed previously in a case series of HIV-infected adults (26). The mechanism for improved treatment outcome is unclear, however it is possible that the immunomodulatory effects of azithromycin may again be contributing to improved recovery in *Cryptosporidium* infection.

367

This study has some limitations. We had no azithromycin susceptibility data from the 368 369 bacterial pathogens tested for in this analysis, however phenotypic resistance in 370 commensal *E.coli* from a subset of ABCD participants from all sites was 24% three 371 months after enrolment. It is possible that azithromycin resistance amongst the Gram-372 negative bacterial pathogens reduced the effect of the azithromycin treatment. 373 Mechanistic studies of azithromycin have shown it exhibits immunomodulatory activity through the regulation of multiple inflammatory pathways (24). Our results may have 374 375 therefore been confounded by children who did not have bacterial attributable diarrhoea 376 but exhibited a treatment response due to the anti-inflammatory activity of azithromycin. 377 In addition, this study of effect heterogeneity was underpowered since the primary 378 ACBD trial was powered for population-level effects. While few estimates of 379 heterogeneity were statistically significant, changes in the magnitude of the 380 azithromycin effect remain informative. Finally, our dataset is derived from children 381 enrolled in the ABCD study, which had restrictive enrolment criteria requiring all children 382 to have dehydration or malnutrition. Therefore, the estimates of the proportions of 383 children who would be treated under varying quantity cut-offs are not generalizable to all

384	children with diarrhoea. Furthermore, the results may not be generalizable to high-		
385	income countries (HICs). Campylobacter spp are endemic and show high sub-clinical		
386	carriage in LMICs but not in HICs (27). It is feasible that there may be a clearer		
387	association between Campylobacter quantity and azithromycin treatment response in		
388	HIC settings where Campylobacter is not endemic.		
389			
390	In this reanalysis of qPCR diagnostic data from the ABCD trial, the relationship between		
391	bacterial quantity and treatment response for Shigella, V. cholerae, tEPEC, and ST-		
392	EAEC support that attribution of diarrhoea aetiology to these pathogens is more		
393	accurate as pathogen quantity increases and suggest that the use of a pathogen		
394	quantity cut-off to attribute aetiology is appropriate for observational and intervention		
395	studies of diarrhoea using molecular diagnostics. However, because the heterogeneity		
396	of treatment response was linear with pathogen quantity, the assignment of an		
397	aetiological qPCR cut-off remains context specific.		
398			
399	Financial support		
400	The ABCD trial and nested molecular diagnostics study was funded by the Bill &		
401	Melinda Gates Foundation (grant numbers OPP 1126331 and OPP 1179069). This		

402 study was funded by the Bill & Melinda Gates Foundation (INV-044317 to ETRM).

403

405 **References**

406 407	1.	Diarrhoeal disease [Internet]. [cited 2024 Apr 24]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/diarrhoeal-disease	
408			
409 410 411 412 413	2.	WHO. World Health Organization Integrated Management of Childhood Illness (IMCI) Chart Booklet—Standard. Geneva (Switzerland): World Health Organization [Internet]. 2014 [cited 2024 Aug 26];(March):1–80. Available from: https://www.who.int/publications/m/item/integrated-management-of-childhood-illness chart-booklet-(march-2014)	
414			
415 416 417	3.	J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, et al. Use of quantitative lecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of GEMS case-control study. The Lancet. 2016 Sep 24;388(10051):1291–301.	
418			
419 420 421	4.	A PM, J L, ET R. Use of quantitative molecular diagnostic methods to assess the tetiology, burden, and clinical characteristics of diarrhoea in children in low-resource settings: a reanalysis of the MAL-ED cohort study. Lancet Glob Health. 6:e1309-18.	
422			
423 424 425 426	5.	Cohen AL, Platts-Mills JA, Nakamura T, Operario DJ, Antoni S, Mwenda JM, et al. Aetiology and incidence of diarrhoea requiring hospitalisation in children under 5 years o age in 28 low-income and middle-income countries: findings from the Global Pediatric Diarrhea Surveillance network. BMJ Glob Health. 2022 Sep 1;7(9):e009548.	
427			
428 429 430	6.	Ahmed T, Chisti MJ, Rahman MW, Alam T, Ahmed D, Parvin I, et al. Effect of 3 Days of Oral Azithromycin on Young Children with Acute Diarrhea in Low-Resource Settings: A Randomized Clinical Trial. JAMA Netw Open. 2021 Dec 16;4(12).	
431			
432 433 434 435	7.	Pavlinac PB, Platts-Mills JA, Liu J, Atlas HE, Gratz J, Operario D, et al. Azithromycin for Bacterial Watery Diarrhea: A Reanalysis of the AntiBiotics for Children With Severe Diarrhea (ABCD) Trial Incorporating Molecular Diagnostics. J Infect Dis. 2024 Apr 12;229(4).	
436			
437 438 439	8.	JW S, RW F, SD P. Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. Clin Infect Dis. 45:294–301.	
440			

441 442 443	9.	D V, V T, M SP. Single oral dose of azithromycin versus 5 days of oral erythromycin or antibiotic in treatment of Campylobacter enterocolitis in children: a prospective randomized assessor-blind study. J Pediatr Gastroenterol Nutr. 50:404–10.	
444			
445 446 447	10.	A K, C S, U D, MA S, ML B. Treatment of shigellosis: V. Comparison of azithromycin d ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med. 126:697-)3.	
448			
449 450	11.	W B, A A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J. 22:374–7.	
451			
452 453 454	12.	Team AS. A double-blind placebo-controlled trial of azithromycin to reduce mortality and improve growth in high-risk young children with non-bloody diarrhoea in low resource settings: the Antibiotics for Children with Diarrhoea (ABCD) trial protocol. Trials. 21:71.	
455			
456 457 458 459	13.	Pavlinac PB, Platts-Mills JA, Liu J, Atlas HE, Gratz J, Operario D, et al. Azithromycin for Bacterial Watery Diarrhea: A Reanalysis of the AntiBiotics for Children With Severe Diarrhea (ABCD) Trial Incorporating Molecular Diagnostics. J Infect Dis. 2024 Apr 12;229(4).	
460			
461 462 463	14.	Platts-Mills JA, McQuade ETR. Assigning Pathogen Etiology for Childhood Diarrhea in High-Burden Settings: A Call for Innovative Approaches. J Infect Dis. 2023 Oct ;228(7):814–7.	
464			
465 466 467 468 469	15.	Levine MM, Nasrin D, Acácio S, Bassat Q, Powell H, Tennant SM, et al. Diarrhoeal disease and subsequent risk of death in infants and children residing in low-income and middle-income countries: analysis of the GEMS case-control study and 12-month GEMS 1A follow-on study. Lancet Glob Health [Internet]. 2020 Feb 1 [cited 2024 Aug 26];8(2):e204. Available from: /pmc/articles/PMC7025325/	
470			
471 472 473	16.	Nuzhat S, Das R, Das S, Islam S Bin, Palit P, Haque MA, et al. Antimicrobial resistance in shigellosis: A surveillance study among urban and rural children over 20 years in Bangladesh. PLoS One. 2022 Nov 1;17(11 November).	
474			
475 476 477	17.	Baker KS, Dallman TJ, Ashton PM, Day M, Hughes G, Crook PD, et al. Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: A cross sectional study. Lancet Infect Dis. 2015 Aug 1:15(8):913–21.	

478			
479 480 481	18.	Houpt ER, Ferdous T, Ara R, Ibrahim M, Alam MM, Kabir M, et al. Clinical Outcomes of Drug-resistant Shigellosis Treated with Azithromycin in Bangladesh. Clinical Infectious Diseases. 2021 May 15;72(10):1793–8.	
482			
483 484 485	19.	Feikin DR, Scott JAG, Gessner BD. Use of vaccines as probes to define disease burden. Lancet [Internet]. 2014 May 5 [cited 2024 Aug 26];383(9930):1762. Available from: /pmc/articles/PMC4682543/	
486			
487 488 489 490 491	20.	atts-Mills JA, Liu J, Rogawski ET, Kabir F, Lertsethtakarn P, Siguas M, et al. Use of antitative molecular diagnostic methods to assess the aetiology, burden, and clinical aracteristics of diarrhoea in children in low-resource settings: a reanalysis of the MAL- cohort study. Lancet Glob Health [Internet]. 2018 Dec 1 [cited 2024 Aug];6(12):e1309. Available from: /pmc/articles/PMC6227251/	
492			
493 494 495 496	21.	Liu J, Platts-Mills JA, Juma J, Kabir F, Nkeze J, Okoi C, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet [Internet]. 2016 Sep 24 [cited 2024 Aug 26];388(10051):1291–301. Available from: https://pubmed.ncbi.nlm.nih.gov/27673470/	
497			
498 499 500 501 502	22.	Das SK, Chisti MJ, Sarker MHR, Das J, Ahmed S, Shahunja KM, et al. Long-term impact of changing childhood malnutrition on rotavirus diarrhoea: Two decades of adjusted association with climate and socio-demographic factors from urban Bangladesh. PLoS One [Internet]. 2017 Sep 1 [cited 2024 Apr 24];12(9). Available from: https://pubmed.ncbi.nlm.nih.gov/28877163/	
503			
504 505 506 507 508	23.	Gasparinho C, Piedade J, Mirante MC, Mendes C, Mayer C, Nery SV, et al. Characterization of rotavirus infection in children with acute gastroenteritis in Bengo province, Northwestern Angola, prior to vaccine introduction. PLoS One [Internet]. 2017 Apr 1 [cited 2024 Apr 24];12(4). Available from: https://pubmed.ncbi.nlm.nih.gov/28422995/	
509			
510 511 512	24.	Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of macrolides-A systematic review of the underlying mechanisms. Front Immunol [Internet]. 2018 Mar 13 [cited 2024 Apr 24];9(MAR):326197. Available from: www.frontiersin.org	
E10			

514 515 516	25.	Uchiyama R, Chassaing B, Zhang B, Gewirtz AT. Antibiotic Treatment Suppresses Rotavirus Infection and Enhances Specific Humoral Immunity. J Infect Dis [Internet]. 2014 Jul 7 [cited 2024 Jun 18];210(2):171. Available from: /pmc/articles/PMC4399425/
517		
518 519 520 521	26.	Kadappu KK, Nagaraja M V., Rao P V., Shastry BA. Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. J Postgrad Med [Internet]. 2002 Jul [cited 2024 Jun 18];48(3):179–81. Available from: https://pubmed.ncbi.nlm.nih.gov/12432190/
522		
523 524 525 526 527	27.	Epps SVR, Harvey RB, Hume ME, Phillips TD, Anderson RC, Nisbet DJ. Foodborne Campylobacter: Infections, Metabolism, Pathogenesis and Reservoirs. International Journal of Environmental Research and Public Health 2013, Vol 10, Pages 6292-6304 [Internet]. 2013 Nov 26 [cited 2024 Apr 24];10(12):6292–304. Available from: https://www.mdpi.com/1660-4601/10/12/6292/htm
528		

530 Figure Legends

Figure 1. Modification of the effect of azithromycin on the risk of diarrhoea on day 531 3 by bacterial pathogen quantities detected. For each bacterial pathogen, A: the 532 533 model-predicted risk of diarrhoea on day 3 by pathogen guantity and treatment arm (red 534 = placebo; blue = azithromycin), conditional on sample collection at day 0 and no co-535 detections. B: the risk ratio for azithromycin compared to placebo for diarrhoea on day 3 536 by pathogen quantity adjusted for the day of diarrhoea on which the sample was 537 collected and co-detection of other pathogens. C: the adjusted risk ratio for azithromycin compared to placebo for diarrhoea on day 3, stratified by the presence of a bacterial co-538 aetiology (green = yes; red = no). Pathogen guantity is specified by the cycle threshold 539 540 value from qPCR (i.e., smaller cycle thresholds correspond to higher pathogen quantity detected). Bands on all plots indicate 95% confidence bands. 541

542

543 Figure 2. Modification of the effect of azithromycin on the risk of diarrhoea on day 544 3 by non-bacterial pathogen quantities detected. For each non-bacterial pathogen, 545 A: the model-predicted risk of diarrhoea on day 3 by pathogen quantity and treatment 546 arm (red = placebo; blue = azithromycin), conditional on sample collection at day 0 and 547 no co-detections. B: the risk ratio for azithromycin compared to placebo for diarrhoea on 548 day 3 by pathogen quantity adjusted for the day of diarrhoea on which the sample was 549 collected and co-detection of other pathogens. C: the adjusted risk ratio for azithromycin 550 compared to placebo for diarrhoea on day 3, stratified by the presence of a bacterial co-551 aetiology (green = yes; red = no). Pathogen quantity is specified by the cycle threshold

value from qPCR (i.e., smaller cycle thresholds correspond to higher pathogen quantity
detected). Bands on all plots indicate 95% confidence bands.

554

555 Figure 3. Modification of the effect of azithromycin on rehospitalisation or death 556 by day 90 by bacterial pathogen quantities detected. For each bacterial pathogen, 557 A: the model-predicted risk of rehospitalisation or death by pathogen quantity and 558 treatment arm (red = placebo; blue = azithromycin), conditional on sample collection at 559 day 0 and no co-detections. B: the risk ratio for azithromycin compared to placebo for rehospitalisation or death by pathogen quantity adjusted for the day of diarrhoea on 560 561 which the sample was collected and co-detection of other pathogens. Pathogen quantity 562 is specified by the cycle threshold value from qPCR (i.e., smaller cycle thresholds 563 correspond to higher pathogen quantity detected). Bands on all plots indicate 95% 564 confidence bands.

565

566 Figure 4. Modification of the effect of azithromycin on rehospitalisation or death 567 by day 90 by non-bacterial pathogen quantities detected. For each non-bacterial 568 pathogen, A: the model-predicted risk of rehospitalisation or death by pathogen quantity 569 and treatment arm (red = placebo; blue = azithromycin), conditional on sample 570 collection at day 0 and no co-detections. B: the risk ratio for azithromycin compared to 571 placebo for rehospitalisation or death by pathogen quantity adjusted for the day of 572 diarrhoea on which the sample was collected and co-detection of other pathogens. Pathogen quantity is specified by the cycle threshold value from qPCR (i.e., smaller 573

- 574 cycle thresholds correspond to higher pathogen quantity detected). Bands on all plots
- 575 indicate 95% confidence bands.
- 576
- 577 Figure 5. Prevalence of antibiotic treatment under decision rules that use cycle
- 578 threshold cut-offs to define aetiology and assign treatment. The proportion of
- 579 diarrhoea episodes overall (red line) and diarrhoea episodes with the pathogen detected
- at any quantity (blue line) that would be treated with antibiotics if a given cycle threshold
- 581 were chosen as the cut-off to define aetiology and assign treatment.

582 Table 1. Change in the effect of azithromycin on risk of diarrhoea on day 3 and risk 583 rehospitalisation or death by day 90 for each log10 increase in pathogen quantity 584 detected among children with watery diarrhoea in the AntiBiotics for Children with 585 severe Diarrhoea (ABCD) Trial.

	Ratio of risk ratios (95% confidence inter-		
		Rehospitalisation or	
Pathogen	Diarrhoea on Day 3	death by day 90	
Shigella/EIEC	0.87 (0.77, 0.97)	0.93 (0.76, 1.13)	
V. cholerae	0.89 (0.68, 1.18)	0.96 (0.45, 2.05)	
tEPEC	0.93 (0.85, 1.02)	0.98 (0.84, 1.13)	
Cryptosporidium	0.94 (0.85, 1.03)	0.87 (0.73, 1.04)	
ST-ETEC	0.94 (0.86, 1.02)	1.00 (0.86, 1.15)	
Giardia	0.99 (0.87, 1.13)	1.14 (0.95, 1.38)	
E. bienuesi	1.00 (0.74, 1.36)	0.70 (0.43, 1.15)	
Sapovirus	1.00 (0.88, 1.12)	0.93 (0.74, 1.16)	
EAEC	1.01 (0.93, 1.09)	0.87 (0.76, 1.01)	
Astrovirus	1.06 (0.92, 1.21)	0.99 (0.76, 1.29)	
Norovirus GII	1.06 (0.92, 1.21)	1.04 (0.83, 1.30)	
Campylobacter jejuni/coli	1.08 (0.97, 1.19)	1.01 (0.85, 1.21)	
Adenovirus 40/41	1.09 (0.98, 1.23)	1.13 (0.96, 1.33)	
LT-ETEC	1.10 (0.91, 1.35)	1.17 (0.92, 1.50)	
Rotavirus	1.16 (1.06, 1.26)	0.93 (0.78, 1.12)	









